The Extension Study
The purpose of this study is to investigate a potential new treatment for both chronic and acute Hepatitis B infections.
Hepatitis B is an infectious disease that is caused by the Hepatitis B virus. Even though highly effective vaccines are available, chronic Hepatitis B infections are still a major global health problem, with an estimated 296 million people living with Hepatitis B worldwide.
Current treatments for Hepatitis B are sub-optimal, as complete cure of the Hepatitis B virus infection is rarely achieved, and the virus often returns when the patient discontinues treatment. It is hoped that this study drug is more effective at blocking re-infection by engaging the immune system against the Hepatitis B virus. It is also hoped that the drug’s half-life (which refers to how long the drug stays in the body) is longer than current available treatments.
This clinical trial has been approved by an independent ethics committee, and participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!